Cargando…
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/ https://www.ncbi.nlm.nih.gov/pubmed/31601010 http://dx.doi.org/10.3390/cancers11101517 |
_version_ | 1783465133452820480 |
---|---|
author | Wang, Wan Tsuchiya, Kaoru Kurosaki, Masayuki Yasui, Yutaka Inada, Kento Kirino, Sakura Yamashita, Koji Sekiguchi, Shuhei Hayakawa, Yuka Osawa, Leona Okada, Mao Higuchi, Mayu Takaura, Kenta Maeyashiki, Chiaki Kaneko, Shun Tamaki, Nobuharu Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Asahina, Yasuhiro Enomoto, Nobuyuki Izumi, Namiki |
author_facet | Wang, Wan Tsuchiya, Kaoru Kurosaki, Masayuki Yasui, Yutaka Inada, Kento Kirino, Sakura Yamashita, Koji Sekiguchi, Shuhei Hayakawa, Yuka Osawa, Leona Okada, Mao Higuchi, Mayu Takaura, Kenta Maeyashiki, Chiaki Kaneko, Shun Tamaki, Nobuharu Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Asahina, Yasuhiro Enomoto, Nobuyuki Izumi, Namiki |
author_sort | Wang, Wan |
collection | PubMed |
description | Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. Results: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240–3360 mg), and the median 1M-RDI was 61.9% (7.1–100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08–0.48, p = 0.0004 and HR 0.2, 95% CI 0.08–0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06–0.55, p = 0.002) and hand–foot skin reaction (HR 0.03, 95% CI 0.008–0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. Conclusion: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice. |
format | Online Article Text |
id | pubmed-6826625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68266252019-11-18 Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice Wang, Wan Tsuchiya, Kaoru Kurosaki, Masayuki Yasui, Yutaka Inada, Kento Kirino, Sakura Yamashita, Koji Sekiguchi, Shuhei Hayakawa, Yuka Osawa, Leona Okada, Mao Higuchi, Mayu Takaura, Kenta Maeyashiki, Chiaki Kaneko, Shun Tamaki, Nobuharu Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Asahina, Yasuhiro Enomoto, Nobuyuki Izumi, Namiki Cancers (Basel) Article Background: We aimed to explore the relative dose intensity (RDI) and post-regorafenib treatments in regorafenib therapy. Methods: The medical records of 38 patients treated with regorafenib between July 2017 and June 2019 at our institution were collected. The RDI of regorafenib for the first month (1M-RDI) was calculated. Results: The overall survival (OS) and progression-free survival (PFS) were 12.4 and 3.7 months. The objective response rate and disease control rate were 13.2% and 71.1%. The median total dose of regorafenib in the first month was 2080 mg (240–3360 mg), and the median 1M-RDI was 61.9% (7.1–100%). Patients with 1M-RDI ≥ 50% showed significantly longer OS and PFS than patients with 1M-RDI < 50% (HR 0.19, 95% CI 0.08–0.48, p = 0.0004 and HR 0.2, 95% CI 0.08–0.52, p = 0.0008). A 1M-RDI ≥ 50% (HR 0.18, 95% CI 0.06–0.55, p = 0.002) and hand–foot skin reaction (HR 0.03, 95% CI 0.008–0.16, p < 0.0001) were independently associated with OS. Post-regorafenib therapies were performed in 19 (86.4%) of 22 patients who had stopped regorafenib due to disease progression. Conclusion: A 1M-RDI ≥ 50% is clinically significant. Post-regorafenib therapies are commonly performed in real-world practice. MDPI 2019-10-09 /pmc/articles/PMC6826625/ /pubmed/31601010 http://dx.doi.org/10.3390/cancers11101517 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Wan Tsuchiya, Kaoru Kurosaki, Masayuki Yasui, Yutaka Inada, Kento Kirino, Sakura Yamashita, Koji Sekiguchi, Shuhei Hayakawa, Yuka Osawa, Leona Okada, Mao Higuchi, Mayu Takaura, Kenta Maeyashiki, Chiaki Kaneko, Shun Tamaki, Nobuharu Nakanishi, Hiroyuki Itakura, Jun Takahashi, Yuka Asahina, Yasuhiro Enomoto, Nobuyuki Izumi, Namiki Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice |
title | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice |
title_full | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice |
title_fullStr | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice |
title_full_unstemmed | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice |
title_short | Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice |
title_sort | sorafenib-regorafenib sequential therapy in japanese patients with unresectable hepatocellular carcinoma—relative dose intensity and post-regorafenib therapies in real world practice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826625/ https://www.ncbi.nlm.nih.gov/pubmed/31601010 http://dx.doi.org/10.3390/cancers11101517 |
work_keys_str_mv | AT wangwan sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT tsuchiyakaoru sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT kurosakimasayuki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT yasuiyutaka sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT inadakento sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT kirinosakura sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT yamashitakoji sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT sekiguchishuhei sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT hayakawayuka sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT osawaleona sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT okadamao sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT higuchimayu sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT takaurakenta sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT maeyashikichiaki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT kanekoshun sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT tamakinobuharu sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT nakanishihiroyuki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT itakurajun sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT takahashiyuka sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT asahinayasuhiro sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT enomotonobuyuki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice AT izuminamiki sorafenibregorafenibsequentialtherapyinjapanesepatientswithunresectablehepatocellularcarcinomarelativedoseintensityandpostregorafenibtherapiesinrealworldpractice |